Recent Trends in Preparation of Poly(lactide-co-glycolide) Nanoparticles by Mixing Polymeric Organic Solution with Antisolvent

Table 3

Summary of processing conditions of nanoprecipitation and major characteristics of PLGA nanoparticles.

Polymer (grade)	Solvent	Polymer (%)	Drug (D)	D/P	Size (nm)	EE (%)	Reference
PLGA50 : 50 (0.2 dL/g)	Acetone	2.5	Anastrazole	5	118∼180	37∼62	[74]
RGP d series (n/a)	Acetone	4	Atorvastatin	12	76∼172	3∼51	[75]
PLGA50 : 50 (45–75 kDa)	Acetone-ethanol	2	Azelaic acid	50	252	72	[76]
RGP d 50155	PEG 400	0.3∼1.3	BSA, lysozyme	12.5∼50	95∼394	Up to 35	[77]
PLGA (n/a)	Acetone	1.7	Chelidonine	20	123	83	[78]
PLA (42 kDa)	Acetone-ethanol	0.6	Chloroaluminium	3.33	115	57	[79]
PLGA75 : 25 (10 kDa)	Acetone	1	Coenzyme-Q	10	100	88	[80]
PLGA50 : 50 (7–17 kDa)	Tetrahydrofuran	0.2	Curcumin	100	79	92	[81]
PLGA (n/a)	Acetone	1.25	Docetaxel	10	139	75	[82]
RG502H (n/a)	Acetone	0.375	Docetaxel	0.1, 1	157∼172	17∼23	[83]
PLA-TPGS (25.3 kDa)	Acetone-ethanol	1.01	Docetaxel	n/a	122	80	[84]
RG502 (12 kDa)	Acetone	1.5	Cannabinoid	6∼20	291∼315	71∼90	[85]
PLGA75 : 25 (75–120 kDa)	PC	2	Estradiol benzoate	1.5	ca. 70∼250	67	[86]
PLGA-PEG (34 kDa)	Acetone	0.36	Flurbiprofen	1.67	123	81	[87]
PLGA50 : 50 (40–75 kDa)	Acetone-ethanol	0.88	Loperamide	50	174	41	[88]
RG 502H (n/a)	Acetone	0.375	Melatonin	1, 3, 5	ca. 100	6∼44	[89]
PLGA (n/a)	Acetone	1.67	Coumarin	20	117	88	[90]
PLGA50 : 50 (40.1 kDa)	DMA	2	Norfloxacin	100	323	15	[91]
PLGA (n/a)	Acetone	1	Paclitaxel	2	87	2	[92]
RG502H (n/a)	Acetonitrile	2.5	Paclitaxel	4	<1,000	86	[93]
PLGA50 : 50 (n/a)	Acetone	2	Paclitaxel	1∼10	250∼300	5∼91	[94]
PLGA (60 kDa)	Acetone	0.24	Ropivacaine	0.25, 0.5	163	4	[95]
PLGA50 : 50 (41 kDa)	Acetone	1.25	Testosterone	40	202	27	[96]
PLGA-PEG (n/a)	Acetonitrile	1	Thymoquinone	5	150∼200	3 or 94	[97]
RG502H (12 kDa)	Acetone	2	Tramadol	10	141	74	[98]
PLGA50 : 50 (50–75 kDa)	Acetone	0.5	Xanthone	1.5	96	43	[99]

Note: n/a, not available, not specified.
All abbreviations are the same as those described in Table 1; DMA, dimethylacetamide.